Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

Tara M Babu; Xiaoying Shen; R Scott McClelland; Zijun Wang; Stacy Selke; Chloe Wilkens; Kirsten A Hauge; Christopher L McClurkan; Erin Goecker; Kerry J Laing; David M Koelle; Alexander L Greninger; Michel C Nussenzweig; David C Montefiori; Lawrence Corey; Anna Wald

doi:10.1093/ofid/ofad673

Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine

Open Forum Infect Dis. 2024 Jan 3;11(2):ofad673. doi: 10.1093/ofid/ofad673. eCollection 2024 Feb.

Authors

Tara M Babu¹, Xiaoying Shen², R Scott McClelland^{1

3

4}, Zijun Wang⁵, Stacy Selke¹, Chloe Wilkens¹, Kirsten A Hauge¹, Christopher L McClurkan¹, Erin Goecker¹, Kerry J Laing¹, David M Koelle^{1

3

6

7

8}, Alexander L Greninger^{6

7}, Michel C Nussenzweig^{5

9}, David C Montefiori^{2

10}, Lawrence Corey^{1

6

7}, Anna Wald^{1

4

6

7}

Affiliations

¹ Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
² Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
³ Department of Global Health, University of Washington, Washington, Seattle, USA.
⁴ Department of Epidemiology, University of Washington, Seattle, Washington, USA.
⁵ Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
⁶ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
⁷ Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
⁸ Benaroya Research Institute, Seattle, Washington, USA.
⁹ Howard Hughes Medical Institute, The Rockefeller University, New York, New York, USA.
¹⁰ Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.

Abstract

We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.

Keywords: SARS-CoV-2; antibody; vaccine; virus.

Grants and funding

UM1 AI068614/AI/NIAID NIH HHS/United States